Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYM-2356
- Development stage
- Unknown
- Lead developer
- Samyang Holdings Biopharm Group
- Administration
- Subcutaneous
01
Overview
SYM-2356 is a medical device candidate developed by Samyang Holdings Biopharm Group, currently in early-stage clinical development (Phase 1/2) for medical aesthetics. The product is composed of porous polymeric microspheres, a technology designed to provide immediate structural volume while potentially facilitating tissue ingrowth and stimulating endogenous collagen production. Unlike traditional solid microspheres, the porous architecture of SYM-2356 is intended to enhance the biological integration of the implant within the dermal or subcutaneous layers. It is primarily being developed for soft tissue augmentation and the correction of age-related volume loss.
Beyond the preview
Go deeper on SYM-2356.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYM-2356.